OIS Podcast | Ophthalmology's leading Podcast

Implandata Ophthalmic Products GmbH is putting the task of tracking intraocular pressure into the hands of patients. Company Co-founder and General Manager Max G. Ostermeier shares the story of EyeMate, an implantable micro sensor capable of measuring absolute intraocular pressure continuously or on demand.

Ehsan Sadri, M.D., FACS, FAAO discusses the impact MIGS will have on ophthalmology practices and offers his insights on how ophthalmologist will handle pressure from Obamacare and other external forces going forward.

Kurt Riegger, President and COO of OcuSciences, tells a start-up’s tale. OcuSciences’ OcuMet Beacon is being developed to give optometrists and ophthalmologies the ability to see the onset of disease earlier than ever.

Imprimis Pharmaceuticals is disrupting the compound pharmaceutical industry, a segment of health care that’s undergoing significant regulatory upheaval. The company’s line of ophthalmology drugs could reduce or eliminate the need for post-surgical eye drops. Its approach is drawing support from many, including Dr. Richard Lindstrom, who serves on the company’s board.

Australia-based Opthea is moving forward with clinical trials in the US, testing its OPT-302 compound along and in combination with Lucentis as a potential treatment for Wet AMD. CEO Megan Baldwin explains the company’s approach up until now and its plans going forward.

Josh Makower, MD, literally wrote (or co-wrote) the book on Medtech Innovation. Makower is a general partner in New Enterprise Associates most recent fund, but he’s worked with the firm as a Venture Partner or EIR since 1995. Makower founded ExploraMed I, II, III, and IV Inc., a se-ries of NEA portfolio medical device incubators based on the West Coast that have created eight companies over the pa...

CEO Paul McLean and Medical Director Malik Kahook, MD, explain how they’ll bring Harmoni to the IOL market.

MIGs leader Glaukos Corp. raised over $100 million in an IPO to expand its already command-ing reach in the white hot MIGs Market. Now the company commands a market capitalization close to $1 billion, enriching the venture investors who committed more than $100 million in ven-ture capital to the company. CEO Thomas Burns explains how Glaukos got where it is today and where he sees it – and the ent...

We’re thrilled to be celebrating the one-year anniversary of the OIS Podcast. We hope you enjoyed these tales of innovation as much as we have. To celebrate milestone we reveal and review the interviews that most resonated with our listeners. We re-viewed numbers Six through Ten in our last episode. In this episode, we’ll review the five most listened to podcasts, including one interview with a gu...

We’re thrilled to be celebrating the one-year anniversary of the OIS Podcast. We hope you enjoyed these tales of innovation as much as we have. To celebrate milestone we reveal and review the interviews that most resonated with our listeners.

Oculeve’s stunning acquisition by Allergan last week led us back to a conversation we had with Mark S. Blumenkranz, MD, Professor & Chairman of the Department of Ophthalmology, Stan-ford University. Mark S. Blumenkranz is the H.J. Smead Professor and Chairman of the De-partment of Ophthalmology at Stanford University. He received his Baccalaureate, Master of Medical Science, and MD degrees at...

OIS Co-Chair Emmett Cunningham explains how Clarus will invest new $500m fund in ophthalmology and beyond. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Learn more about: Sponsorship Presenting Companies Any other questions? C...

Oculeve CEO Michael Ackermann Talks About Allergan’s Big Move in Dry Eye. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Learn more about: Sponsorship Presenting Companies Any other questions? Contact the producer of OIS, Craig...

Bausch &Lomb Surgical’s Andrew Chang Has Big Plans in Ophthalmology Surgical. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Learn more about: Sponsorship Presenting Companies Any other questions? Contact the producer of OI...

Hear from Allergan’s Past and Future: Highlights of interviews with Brent Saunders and Gavin Herbert.

Leaders of Alcon, AMO, Valeant and Zeiss Discuss the Role of Innovation in their Success.

Valeant CEO J. Michael Pearson tells OIS attendees how the controversial company finds new technologies. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Learn more about: Sponsorship Presenting Companies Any other questions? Con...

Transcend Medical CMO Sean Ianchulev provides update on COMPASS trial and shares company’s plan for the FDA.

Leonard Borrmann, head of R&D at AMO, explains how the company encourages “failing forward” and other innovative qualities to creating new vision devices. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Learn more about: Spo...

Veteran Ophthalmology Scribes Larry Haimovich of Haimovitch Medical Technol-ogy Consultants and Mike Lachman of EyeQ Research put down the pens and pick up the Mics to share their insights on ophthalmology.

David Muller, CEO of Avedro, addresses delays in the FDA’s review of the company’s riboflavin ophthalmic solution/KXL System for corneal cross-linking and discusses the considerable potential of PIXL.

OIS Co-Chair Bill Link interviews Richard Lindstrom, MD, after awarding him with the Ophthalmology Innovator Award at OIS@ASCRS on April 16 in San Diego.

The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Learn more about: Sponsorship Presenting Companies Any other questions? Contact the producer of OIS, Craig Simak .

As venture investors shift to later stages, start-ups will have to look harder for new sources of innovation. A panel at OIS@ASCRS discusses how new sources of capital can sustain the creation of new companies.

For 10 years PowerVision has been advancing its accommodating IOL, Flu-idVision. Co-Founder, CEO and President Barry Cheskin explains how the company has kept its focus on someday capturing a huge piece of the IOL market. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executiv...